Viemed Healthcare, Inc. (VMD) Stock Price & Analysis
Viemed Healthcare, Inc. (VMD) rose 0.00% to USD 9.92 as of June 10, 2026 at 10:43 UTC, according to Nexqual real-time market data.
VMD last closed at USD 9.92; the session ranged USD 9.87–10.06 on volume of 203,458 shares. Market capitalization is $380.30M, with a 52-week range of USD 5.93–10.19 (NCM). Source: Nexqual, June 10, 2026 at 10:43 UTC.
Key Statistics (as of June 10, 2026 at 10:43 UTC)
| Price | USD 9.92 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 9.92 |
| Open | USD 9.89 |
| Day Range | USD 9.87 – 10.06 |
| 52-Week Range | USD 5.93 – 10.19 |
| Volume | 203,458 shares |
| Market Cap | $380.30M |
| Exchange | NCM |
Technical Analysis (VMD)
Nexqual's technical model rates VMD "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 10:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.06 (neutral) |
| vs SMA50 | Above (USD 9.59) |
| MACD | 0.1 (positive) |
Analyst Ratings (VMD)
Wall Street analysts rate VMD "None" based on 1 analysts, with a mean price target of USD 11 (range USD 11–11), per Nexqual as of June 10, 2026 at 10:43 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 11 |
| High Target | USD 11 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (VMD)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $78.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.06 vs est 0.09 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.13 ▲ beat |
| 2025-09-30 | USD 0.09 vs est 0.09 ▲ beat |
| 2025-06-30 | USD 0.08 vs est 0.09 ▼ miss |
Source: Nexqual, June 10, 2026 at 10:43 UTC.
Financials & Fundamentals (VMD)
| Total Revenue | $286.56M |
|---|---|
| Revenue Growth (YoY) | +27.50% |
| Gross Margin | +57.58% |
| Operating Margin | +6.27% |
| Profit Margin | +5.20% |
| ROE | +10.89% |
| Debt / Equity | 8.53 |
| Current Ratio | 1.22 |
| Total Cash | $9.76M |
| Total Debt | $12.44M |
| Free Cash Flow | $28.27M |
Source: Nexqual, June 10, 2026 at 10:43 UTC.
Financial Health Score (VMD)
Nexqual rates Viemed Healthcare, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 10:43 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 58%, operating 6% |
| Balance Sheet | Strong — $10M cash vs $12M debt |
| Cash Flow | Solid — FCF $28M, 10% margin |
| Efficiency | Mixed — ROE 11%, ROA 8.3% |
Ownership (VMD)
| Insider Ownership | +13.92% |
|---|---|
| Institutional Ownership | +69.64% |
| Shares Outstanding | 38.34M |
| Float | 30.25M |
| Short % of Float | +1.52% |
Source: Nexqual, June 10, 2026 at 10:43 UTC.
Leadership (VMD)
Viemed Healthcare, Inc. is led by Casey Hoyt (age 48), CEO & Director, per Nexqual as of June 10, 2026 at 10:43 UTC.
| CEO & Director | Casey Hoyt (age 48) |
|---|---|
| President | Michael B. Moore CRT (age 48) |
| Chief Financial Officer | Trae Paul Fitzgerald (age 37) |
| COO & Director | William Todd Zehnder (age 50) |
| Chief Medical Officer & Director | William Dana Frazier (age 67) |
Major Backers & Investors (VMD)
Notable institutional backers of Viemed Healthcare, Inc. include Forager Capital Management, LLC, Goldman Sachs, Ameriprise Financial, Inc., according to Nexqual as of June 10, 2026 at 10:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Forager Capital Management, LLC | 7.37% |
| Goldman Sachs | 4.25% |
| Ameriprise Financial, Inc. | 2.34% |
| Nantahala Capital Management, LLC | 2.31% |
| Arrowstreet Capital, Limited Partnership | 1.86% |
| Punch & Associates Investment Management, Inc. | 1.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.53% |
| Vanguard Group | 6.72% |
| Geode Capital | 2.03% |
| State Street | 1.94% |
Source: Nexqual, June 10, 2026 at 10:43 UTC.
From Viemed Healthcare, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States.
- The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
- It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment.
- In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLGN | CollPlant Biotechnologies Ltd. | USD 0.37 | ▲ 0% |
| FKWL | Franklin Wireless Corp. | USD 2.78 | ▼ 2.8% |
| SIBN | SI-BONE, Inc. | USD 15.53 | ▲ 2.71% |
| VREX | Varex Imaging Corporation | USD 10.62 | ▲ 5.25% |
| INFU | InfuSystems Holdings, Inc. | USD 9.01 | ▼ 2.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:43 UTC. This page is informational and not investment advice.